Jubilant Therapeutics, a precision oncology and immunology-focused biotech, is set to begin Phase II and first-in-human trials in 2023 with two Orphan Drug Designations. Their pipeline is generated entirely in-house using their unique discovery engine called the Therapeutic Index and Brain Exposure Optimization (TIBEO) which identifies candidate molecules with enhanced therapeutic indices that can penetrate the brain to achieve pharmacologically active concentrations. The lead program, JBI-802, is an oral inhibitor of coREST that has been granted Orphan Drug Designation for neuroendocrine small cell lung cancer (SCLC) and AML by the FDA. In preclinical testing, JBI-802 demonstrated anti-tumor activity superior to that achieved by inhibitors of either LSD1 or HDAC6 alone.
Jubilant's second clinical-stage drug candidate is JBI-778, a third-generation protein arginine methyltransferase 5 (PRMT5) inhibitor that targets tumors with mutations in spliceosome proteins. Jubilant also has two other disclosed programs in preclinical development on IND track: a first-in-class peptidylarginine deiminase